Welcome!

News Feed Item

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_eu_analysis_market_forecasts.html

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

Summary

Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions.

While there are significant barriers facing this market, current and future players can still position themselves to obtain a competitive advantage. The major European countries included in this forecast have general mass screening programs for breast cancer detection and they will be increasing their adoption of more expensive VAB devices. Additionally, the emerging economies will see an increased shift from fine needle aspiration devices to more expensive core biopsy devices over the forecast.

Scope

- An overview of biopsy devices, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized EU biopsy devices market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019.
- Investigation of current and future market competition for biopsy devices
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the biopsy devices sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL).

Reasons to buy

- Understand the trends shaping and driving EU biopsy devices Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in EU biopsy devices market through 2019.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in EU biopsy devices market landscape? Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Overview 14
2.2 Catalyst 15
2.3 Related Reports 15
3 Industry Overview 16
3.1 Types of Biopsies 16
3.1.1 Surgical Biopsy 16
3.1.2 Fine Needle Aspiration 16
3.1.3 Core Needle Biopsy 17
3.1.4 Vacuum-Assisted Biopsy 18
3.2 Biopsy Procedure Trends 18
3.2.1 EU 18
3.3 Market Access to Cancer Screening Programs 24
3.3.1 Regulation 24
3.3.2 Biopsy Device Adoption Patterns 27
3.3.3 Reimbursement Trends 31
3.4 Regulatory Issues/Recalls 33
3.5 Mergers & Acquisitions/Key Partnerships 34
3.5.1 Hologic Acquires Suros Surgical Systems 34
3.5.2 C. R. Bard Acquires SenoRx 34
3.5.3 Devicor Medical Products Acquires Breast Care Portfolio from Ethicon Endo-Surgery 34
3.6 Economic Impact of Cancer Screening and Treatment 35
3.7 Additional Indications for Biopsy Devices 36
4 Unmet Needs 37
4.1 Overview 37
4.2 More Efficient Screening Tests for Prostate Cancer 37
4.3 More Efficient Screening Tests for Breast Cancer 38
4.4 More Efficient Screening Guidelines for Thyroid Cancer 38
4.5 Screening Tests That Can Provide Histological Analysis In Situ 39
5 Market Opportunity Analysis 40
5.1 Increase Marketing for Vacuum-Assisted Biopsy Devices in European Countries 40
5.2 Bundling Solutions 41
5.3 Focus Efforts on China's Increasing Adoption of VAB Devices 42
5.4 Market for Prostate Cancer Screening Coverage in Europe 42
6 Market Drivers and Barriers 44
6.1 Market Drivers 44
6.1.1 Inadequate Screening Tests for Particular Cancers 44
6.1.2 Demand for Minimally-Invasive Biopsy Techniques 45
6.1.3 Increased Adherence to Certain Cancer Screening Guidelines 45
6.1.4 Aging Patient Population 46
6.2 Market Barriers 47
6.2.1 Increased Competition from Other Cancer Diagnostic Tests 47
6.2.2 Breast Biopsy Reimbursement Bundling 50
6.2.3 Decreased Adherence to Certain Cancer Screening Guidelines 52
6.2.4 Benefits of Mass Prostate Cancer Screening Being Outweighed by Risks 53
7 Competitive Assessment 55
7.1 Overview 55
7.2 Classification Based on System 55
7.2.1 Vacuum-Assisted Biopsy Devices 55
7.2.2 Core Needle Biopsy Devices 57
7.2.3 Fine Needle Aspiration Devices 58
8 Pipeline Assessment 60
8.1 Overview 60
8.1.1 Optical Biopsy 61
8.1.2 Liquid Biopsy 62
9 Clinical Trial Analysis 63
10 Current and Future Players 65
10.1 Trends in Corporate Strategy 65
10.2 Company Profiles 65
10.2.1 Argon Medical Devices 65
10.2.2 Boston Scientific 68
10.2.3 Cardinal Health 71
10.2.4 CareFusion Corporation 72
10.2.5 Cook Medical 74
10.2.6 C. R. Bard 77
10.2.7 Devicor Medical Products 83
10.2.8 DTR Medical 87
10.2.9 Gallini Medical Devices 88
10.2.10 Hologic 91
10.2.11 INRAD 94
10.2.12 Intact Medical Corporation 96
10.2.13 TSK Laboratory 98
11 Market Outlook 100
11.1 Company Market Share 100
11.1.1 Vacuum-Assisted Biopsy Market Share 100
11.1.2 Core Needle Biopsy/Fine Needle Aspiration Market Share 102
11.2 By Segment 103
11.2.1 Fine Needle Aspiration 103
11.2.2 Core Needle Biopsy 104
11.2.3 Vacuum-Assisted Biopsy 105
11.3 By Geography 106
11.3.1 France 106
11.3.2 Germany 107
11.3.3 Italy 109
11.3.4 Spain 110
11.3.5 United Kingdom 112
12 Appendix 114
12.1 Bibliography 114
12.2 Abbreviations 123
12.3 Report Methodology 125
12.3.1 Overview 125
12.3.2 Coverage 125
12.3.3 Primary Research 125
12.3.4 Secondary Research 126
12.3.5 Forecasting Methodology 127
12.4 Key Opinion Leaders Included in This Study 127
12.5 About the Authors 128
12.5.1 Joseph A. Gregory, Analyst, Surgical Devices 128
12.5.2 Derek Archila, MBA, Director of Research and Analysis, Medical Devices 128
12.6 Global Head of Healthcare 129
12.6.1 Bonnie Bain, Ph.D., Global Head of Healthcare 129
12.7 About MediPoint 130
12.8 About GlobalData 130
12.9 Disclaimer 130

List of Tables

Table 1: Breast Cancer Incidence Rates, 5EU, 2010-2019 21
Table 2: Biopsy Device Adoption Patterns in Diagnosing Prostate Cancer, Global, 2013 and 2019 28
Table 3: Biopsy Device Adoption Patterns in Diagnosing Breast Cancer, Global, 2013 and 2019 29
Table 4: Biopsy Device Adoption Patterns in Diagnosing Lung Cancer, Global, 2013 and 2019 30
Table 5: Biopsy Device Adoption Patterns in Diagnosing Liver Cancer, Global, 2013 and 2019 30
Table 6: Biopsy Device Adoption Patterns in Diagnosing Thyroid Cancer, Global, 2013 and 2019 31
Table 7: Age Demographics, Age >65 Years, Global, 2013 46
Table 8: Stereotactic Breast Biopsy Ambulatory Surgery Center Billing, 2011 51
Table 9: Stereotactic Breast Biopsy Physician Billing, 2011 51
Table 10: Company Profile - Argon Medical Devices 66
Table 11: Product Portfolio - Argon Medical Devices 67
Table 12: Argon Medical Devices, SWOT Analysis, 2013 67
Table 13: Company Profile - Boston Scientific 68
Table 14: Product Portfolio - Boston Scientific 70
Table 15: Boston Scientific SWOT Analysis, 2013 70
Table 16: Company Profile - Cardinal Health 71
Table 17: Product Portfolio - Cardinal Health 72
Table 18: Cardinal Health SWOT Analysis, 2013 72
Table 19: Company Profile - CareFusion Corporation 73
Table 20: Product Portfolio - CareFusion 74
Table 21: CareFusion, SWOT Analysis, 2013 74
Table 22: Company Profile - Cook Medical 75
Table 23: Product Portfolio - Cook Medical 76
Table 24: Cook Medical, SWOT Analysis, 2013 77
Table 25: Company Profile - C. R. Bard 78
Table 26: Product Portfolio - C. R. Bard 78
Table 27: C.R. Bard, SWOT Analysis, 2013 82
Table 28: Company Profile - Devicor Medical Products 83
Table 29: Product Portfolio - Devicor Medical Products 86
Table 30: Devicor Medical Products SWOT Analysis, 2013 86
Table 31: Company Profile - DTR Medical 87
Table 32: Product Portfolio - DTR Medical 87
Table 33: DTR Medical SWOT Analysis, 2013 88
Table 34: Company Profile - Gallini Medical Devices 89
Table 35: Product Portfolio - Gallini Medical Devices 90
Table 36: Gallini Medical Devices SWOT Analysis, 2013 90
Table 37: Company Profile - Hologic 91
Table 38: Product Portfolio - Hologic 93
Table 39: Hologic SWOT Analysis, 2013 93
Table 40: Company Profile - INRAD 94
Table 41: Product Portfolio - INRAD 95
Table 42: INRAD SWOT Analysis, 2013 95
Table 43: Company Profile - Intact Medical Corporation 96
Table 44: Product Portfolio - Intact Medical Corporation 97
Table 45: Intact Medical Corporation SWOT Analysis, 2013 97
Table 46: Company Profile - TSK Laboratory 98
Table 47: Product Portfolio - TSK Laboratory 99
Table 48: TSK Laboratory SWOT Analysis, 2013 99
Table 49: VAB, Global Market Share, 2013 101
Table 50: CNB/FNA, Global Market Share, 2013 102
Table 51: EU FNA Device Sales ($m) Forecast, 2010-2019 103
Table 52: EU CNB Device Sales ($m) Forecast, 2010-2019 104
Table 53: EU VAB Device Sales ($m) Forecast, 2010-2019 105
Table 54: France Biopsy Devices Sales ($m) Forecast, 2010-2019 106
Table 55: Germany Biopsy Devices Sales ($m) Forecast, 2010-2019 108
Table 56: Italy Biopsy Devices Sales ($m) Forecast, 2010-2019 109
Table 57: Spain Biopsy Devices Sales ($m) Forecast, 2010-2019 111
Table 58: United Kingdom Biopsy Devices Sales ($m) Forecast, 2010-2019 112

List of Figures

Figure 1: Biopsy Procedure Volumes: Prostate, 5EU, 2010-2019 19
Figure 2: Biopsy Procedure Volumes: Breast, 5EU, 2010-2019 20
Figure 3: Biopsy Procedure Volumes: Lung, 5EU, 2010-2019 22
Figure 4: Biopsy Procedure Volumes: Liver, 5EU, 2010-2019 23
Figure 5: Biopsy Procedure Volumes: Thyroid, 5EU, 2010-2019 24
Figure 6: EnCor Breast Biopsy System 79
Figure 7: EnCor Enspire Breast Biopsy System 80
Figure 8: EnCor Ultra Breast Biopsy System 80
Figure 9: Finesse Ultra Breast Biopsy System 81
Figure 10: Vacora Breast Biopsy System 82
Figure 11: Original Mammotome System 84
Figure 12: Mammotome Elite 85
Figure 13: Mammotome Revolve 86
Figure 14: VAB, Global Market Share, 2013 101
Figure 15: CNB/FNA, Global Market Share, 2013 102
Figure 16: EU FNA Device Sales ($m) Forecast, 2010-2019 103
Figure 17: EU CNB Device Sales ($m) Forecast, 2010-2019 104
Figure 18: EU VAB Device Sales ($m) Forecast, 2010-2019 105
Figure 19: France Biopsy Devices Sales ($) Forecast, 2010-2019 107
Figure 20: Germany Biopsy Devices Sales ($) Forecast, 2010-2019 108
Figure 21: Italy Biopsy Devices Sales ($) Forecast, 2010-2019 110
Figure 22: Spain Biopsy Devices Sales ($) Forecast, 2010-2019 111
Figure 23: United Kingdom Biopsy Devices Sales ($) Forecast, 2010-2019 113

Read the full report:
MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_eu_analysis_market_forecasts.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Most of the time there is a lot of work involved to move to the cloud, and most of that isn't really related to AWS or Azure or Google Cloud. Before we talk about public cloud vendors and DevOps tools, there are usually several technical and non-technical challenges that are connected to it and that every company needs to solve to move to the cloud. In his session at 21st Cloud Expo, Stefano Bellasio, CEO and founder of Cloud Academy Inc., will discuss what the tools, disciplines, and cultural...
The “Digital Era” is forcing us to engage with new methods to build, operate and maintain applications. This transformation also implies an evolution to more and more intelligent applications to better engage with the customers, while creating significant market differentiators. In both cases, the cloud has become a key enabler to embrace this digital revolution. So, moving to the cloud is no longer the question; the new questions are HOW and WHEN. To make this equation even more complex, most ...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory?
SYS-CON Events announced today that App2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. App2Cloud is an online Platform, specializing in migrating legacy applications to any Cloud Providers (AWS, Azure, Google Cloud).
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
WebRTC is great technology to build your own communication tools. It will be even more exciting experience it with advanced devices, such as a 360 Camera, 360 microphone, and a depth sensor camera. In his session at @ThingsExpo, Masashi Ganeko, a manager at INFOCOM Corporation, will introduce two experimental projects from his team and what they learned from them. "Shotoku Tamago" uses the robot audition software HARK to track speakers in 360 video of a remote party. "Virtual Teleport" uses a mu...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
Trying to improve density, lower costs and run applications faster than before? Today, enterprises looking for a secure cloud strategy are increasingly turning to container-based Platform as a Service solutions for on-premises hosted DevOps. In her session at 21st Cloud Expo, Alise Cashman Spence, Offering Manager, Power Systems Cloud Solutions at IBM, will discuss the driving factors behind these cloud trends and how IBM customers are realizing exceptional performance, security and control for ...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In their Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, and Mark Lav...
SYS-CON Events announced today that SourceForge has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SourceForge is the largest, most trusted destination for Open Source Software development, collaboration, discovery and download on the web serving over 32 million viewers, 150 million downloads and over 460,000 active development projects each and every month.
"NetApp's vision is how we help organizations manage data - delivering the right data in the right place, in the right time, to the people who need it, and doing it agnostic to what the platform is," explained Josh Atwell, Developer Advocate for NetApp, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
What You Need to Know You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technolog...